Tumor RNA-loaded nanoliposomes increases the anti-tumor immune response in colorectal cancer

References

• Charbe NB, Amnerkar ND, Ramesh B, et al. (2020). Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharm Sin B 10:2075–109.
   PubMed Web of Science ®Google Scholar
• Cheung LS, Chen L, Oke TF, et al. (2021). Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. J Immunother Cancer 9:e002345.
   PubMed Web of Science ®Google Scholar
• Fan Y, Kuai R, Xu Y, et al. Nl. (2017). Immunogenic cell death amplified by Co-localized adjuvant delivery for cancer immunotherapy. Nano Lett 17:7387–93.
   PubMed Web of Science ®Google Scholar
• Fu D, Wu J, Lai J. (2020). T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colorectal cancer. Am J Cancer Res 10:473–90.
   PubMed Web of Science ®Google Scholar
• Gao J, Chen H, Yu Y, et al. (2013). Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials 34:10084–98.
   PubMed Web of Science ®Google Scholar
• Gao J, Liu W, Xia Y, et al. (2011). The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32:3459–70.
   PubMed Web of Science ®Google Scholar
• Gao J, Yu Y, Zhang Y, et al. (2012). EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials 33:270–82.
   PubMed Web of Science ®Google Scholar
• Golchin S, Alimohammadi R, Rostami Nejad M, Jalali SA. (2019). Synergistic antitumor effect of anti-PD-L1 combined with oxaliplatin on a mouse tumor model. J Cell Physiol 234:19866–74.
   PubMed Web of Science ®Google Scholar
• Heiser A, Maurice MA, Yancey DR, et al. (2001a). Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 61:3388–93.
   PubMed Web of Science ®Google Scholar
• Heiser A, Maurice MA, Yancey DR, et al. (2001b). Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 166:2953–60.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kobuchi S, Takeda M, Morimoto M. (2020). Effect of intact oxaliplatin in plasma on a cold allodynia after multiple administrations in colorectal cancer model rats. Ann Palliat Med 9:3000–6.
   PubMed Web of Science ®Google Scholar
• Li S, Huang L. (2006). Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 3:579–88.
   PubMed Web of Science ®Google Scholar
• Ma K, Mi CL, Cao XX, Wang TY. (2021). Progress of cationic gene delivery reagents for non-viral vector. Appl Microbiol Biotechnol 105:525–38.
   PubMed Web of Science ®Google Scholar
• Markov V, Mironova NL, Shmendel EV, et al. (2017). Systemic delivery of complexes of melanoma RNA with mannosylated liposomes activates highly efficient murine melanoma-specific cytotoxic T cells in vivo. Mol Biol 51:118–25.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang Y, Huang L. (2021). mRNA vaccine for cancer immunotherapy. Mol Cancer 20:41.
   PubMed Web of Science ®Google Scholar
• Naka T, Iwahashi M, Nakamura M, et al. (2008). Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA. Cancer Sci 99:407–13.
   PubMed Web of Science ®Google Scholar
• Paulines MJ, Limbach PA. (2017). Stable isotope labeling for improved comparative analysis of RNA digests by mass spectrometry. J Am Soc Mass Spectrom 28:551–61.
   PubMed Web of Science ®Google Scholar
• Powell D, Chandra S, Dodson K, et al. (2017). Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm 114:108–18.
   PubMed Web of Science ®Google Scholar
• Rossi JF, Lu ZY, Massart C, Levon K. (2021). Dynamic immune/inflammation precision medicine: the good and the bad inflammation in infection and cancer. Front Immunol. 12:595722.
   PubMed Web of Science ®Google Scholar
• Sales de Sa R, Miranda Galvis M, Mariz B, et al. (2020). Increased Tumor immune microenvironment CD3+ and CD20+ lymphocytes predict a better prognosis in oral tongue squamous cell carcinoma. Front Cell Dev Biol 8:622161.
   PubMed Web of Science ®Google Scholar
• Saxena M, Bhardwaj N. (2018). Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer 4:119–37.
   PubMed Web of Science ®Google Scholar
• Sayour EJ, Mendez-Gomez HR, Mitchell DA. (2018). Cancer vaccine immunotherapy with RNA-loaded liposomes. Int J Mol Sci 19:2890.
   PubMed Web of Science ®Google Scholar
• Shahnazari M, Samadi P, Pourjafar M, Jalali A. (2020). Therapeutic vaccines for colorectal cancer: the progress and future prospect. Int Immunopharmacol 88:106944.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Wood L, Gandhapudi S, Sundarapandiyan K, et al. (2020). DOTAP (Versamune): a novel enantiospecific cationic lipid nanoparticle that induces CD4 and CD8 cellular immune responses to whole protein and tumor-specific peptide antigens. J Clin Oncol 38:e15211–e15211.
   Web of Science ®Google Scholar
• Yang R, Xu J, Xu L, et al. (2018). Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano 12:5121–9.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xie C, Wang D, et al. (2019). Improved antitumor efficacy of combined vaccine based on the induced HUVECs and DC-CT26 against colorectal carcinoma. Cells 8:494.
   PubMed Web of Science ®Google Scholar